Summary
Over 1,500 pages analysing the structure, performance and research of more than 120 leading cancer drug development companies - now available.
Cancer continues to dominate industry research and investment as the search for really effective therapies hots up. The commercial rewards for companies that make significant breakthroughs in the cure or control of key cancers such as breast, ovarian, lung and prostate are considerable.
The application of biotechnology to the identification and development of drug candidates has seen a variety of novel paths pursued by a range of development companies.
For analysts, investors and pharmaceutical company executives, being able to readily and easily assess these companies, the research they are pursuing, products being developed, collaborators and financial performance/funding is key to understanding this sector of the market.
That is why the new 6th edition of this respected management report, Who's Developing What in New Cancer Drugs? is the essential reference work for everyone in the field. The report covers 121 companies - from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.
For each company you can evaluate:
- Summary: At a glance review of agreements, products and R&D pipeline.
- Overview: Background, technology and research techniques they have developed for drug discovery.
- Agreements: Key details of who the company is collaborating with, and on what.
- Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
- R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
- Financial: An analysis of financial performance including P&L, R&D expenditure and funding.
Companies Analysed
- Access Pharmaceuticals
- Active Biotech
- ADVENTRX Pharmaceuticals
- AEterna Zentaris
- Alchemia
- Alfacell
- Allos Therapeutics
- Ambrilia Biopharma
- Amgen
- Angiogene Pharmaceuticals
- AntiCancer
- Antigenics
- Antisense Pharma
- Antisoma
- ARIAD Pharmaceuticals
- ARIUS Research
- Ark Therapeutics
- ArQule
- Array BioPharma
- AstraZeneca
- Attenuon
- AVAX Technologies
- Bayer
- Biogen Idec
- Biomira
- BioNumerik Pharmaceuticals
- BioVex
- Bristol-Myers Squibb
- BTG International
- Callisto Pharmaceuticals
- Can-Fite BioPharma
- CEL-SCI
- Celgene
- Cell Genesys
- Cell Therapeutics
- Cephalon
- Clavis Pharma
- Coley Pharmaceutical
- Curagen Corporation
- Cyclacel Pharmaceuticals
- Cytokinetics
- Daiichi Sankyo
- Dendreon
- Eli Lilly
- Endocyte
- EntreMed
- Enzon Pharmaceuticals
- EpiCept
- Exelixis
- Favrille
- Gamida Cell
- Genentech
- Genitope
- Genmab
- Genta
- GenVec
- Genzyme Oncology
- Geron
- GlaxoSmithKline
- GPC Biotech
- Hana Biosciences
- Human Genome Sciences
- Idera Pharmaceuticals
- IDM Pharma
- ImClone Systems
- ImmunoGen
- Immunomedics
- Introgen Therapeutics
- Isis Pharmaceuticals
- Keryx Biopharmaceuticals
- Kirin Holdings Company
- Kosan Biosciences
- Kyowa Hakko Kogyo
- Ligand Pharmaceuticals
- Lorus Therapeutics
- Marshall Edwards
- Medarex
- MediGene
- Merck KGaA
- MethylGene
- MGI Pharma
- Micromet Millennium Pharmaceuticals
- NeoPharm
- Northwest Biotherapeutics
- Novacea
- Novartis
- OncoGenex Technologies
- Oncolytics Biotech
- Onyvax
- Onyx Pharmaceuticals
- OSI Pharmaceuticals
- Oxford BioMedica
- OXiGENE
- Panacea Pharmaceuticals
- Peregrine Pharmaceuticals
- Pfizer
- Pharmacyclics
- PharmaMar
- PhotoCure
- Progen Industries
- Progenics Pharmaceuticals
- Protherics
- Quest PharmaTech
- Roche
- sanofi-aventis
- Schering-Plough
- Seattle Genetics
- Spectrum Pharmaceuticals
- SuperGen
- Synta Pharmaceuticals
- Tekmira Pharmaceuticals
- Telik
- TopoTarget
- Transgene
- Vical
- Vion Pharmaceuticals
- ViRexx Medical
- Viventia Biotech
- Wilex
- YM Bioscience
The new 6th edition of this respected management report is the essential reference work for everyone in the field. The report covers121 companies - from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.
|
